CL2016001586A1 - Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 - Google Patents

Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40

Info

Publication number
CL2016001586A1
CL2016001586A1 CL2016001586A CL2016001586A CL2016001586A1 CL 2016001586 A1 CL2016001586 A1 CL 2016001586A1 CL 2016001586 A CL2016001586 A CL 2016001586A CL 2016001586 A CL2016001586 A CL 2016001586A CL 2016001586 A1 CL2016001586 A1 CL 2016001586A1
Authority
CL
Chile
Prior art keywords
agonist
ang2 antibody
therapy combined
therapy
combined
Prior art date
Application number
CL2016001586A
Other languages
English (en)
Inventor
Christian Klein
Markus Thomas
Philipp Mueller
Alfred Zippelius
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2016001586A1 publication Critical patent/CL2016001586A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCIÓN PROPORCIONA UNA TERAPIA COMBINADA CON UN ANTICUERPO ANTI-ANG2 Y UN AGONISTA DE CD40
CL2016001586A 2013-12-20 2016-06-17 Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 CL2016001586A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13198753 2013-12-20
EP14158331 2014-03-07

Publications (1)

Publication Number Publication Date
CL2016001586A1 true CL2016001586A1 (es) 2017-05-12

Family

ID=52278610

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001586A CL2016001586A1 (es) 2013-12-20 2016-06-17 Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40

Country Status (20)

Country Link
US (3) US20150232548A1 (es)
EP (1) EP3082857B1 (es)
JP (1) JP6345787B2 (es)
KR (1) KR20160085888A (es)
CN (1) CN105611944A (es)
AU (1) AU2014368695A1 (es)
BR (1) BR112016007112A2 (es)
CA (1) CA2923591A1 (es)
CL (1) CL2016001586A1 (es)
CR (1) CR20160199A (es)
EA (1) EA201600474A1 (es)
HK (1) HK1221409A1 (es)
IL (1) IL244454A0 (es)
MX (1) MX2016008099A (es)
PE (1) PE20160753A1 (es)
PH (1) PH12016500482A1 (es)
SG (1) SG11201604594SA (es)
TW (1) TWI559931B (es)
WO (1) WO2015091655A1 (es)
ZA (1) ZA201601895B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
EP3180087B1 (en) 2014-08-12 2019-03-13 Alligator Bioscience AB Combination therapies with anti cd40 antibodies
SG11201702550WA (en) 2014-11-10 2017-04-27 Hoffmann La Roche ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗体及び眼科に使用する方法
WO2016075035A1 (en) * 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
PE20180315A1 (es) 2015-06-29 2018-02-09 Bristol Myers Squibb Co Anticuerpos para cd40
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
AR113862A1 (es) * 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
CN111788227B (zh) 2017-12-27 2025-02-25 百时美施贵宝公司 抗cd40抗体及其用途
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US11242396B2 (en) * 2018-10-01 2022-02-08 Hoffmann-La Roche Inc. Bispecific antigen binding molecules comprising anti-FAP clone 212
US20220204603A1 (en) * 2019-02-25 2022-06-30 Pharmabcine Inc. Anti-ang2 antibody and use thereof
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
TWI877179B (zh) * 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
CN112168960A (zh) * 2019-07-03 2021-01-05 义慧科技(深圳)有限公司 抗VEGF抗体和抗ANG2抗体在制备治疗具有Ras突变的肿瘤的药物中的应用
EP4027998A1 (en) 2019-09-09 2022-07-20 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
KR20250128899A (ko) * 2024-02-20 2025-08-28 주식회사 맵틱스 Tie2 및 VEGF에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma

Also Published As

Publication number Publication date
HK1221409A1 (zh) 2017-06-02
WO2015091655A1 (en) 2015-06-25
CA2923591A1 (en) 2015-06-25
SG11201604594SA (en) 2016-07-28
TWI559931B (en) 2016-12-01
ZA201601895B (en) 2018-11-28
EA201600474A1 (ru) 2016-11-30
AU2014368695A1 (en) 2016-04-14
CN105611944A (zh) 2016-05-25
EP3082857A1 (en) 2016-10-26
EP3082857B1 (en) 2018-07-25
CR20160199A (es) 2016-06-17
US20180134780A1 (en) 2018-05-17
KR20160085888A (ko) 2016-07-18
JP6345787B2 (ja) 2018-06-20
MX2016008099A (es) 2016-10-13
TW201526915A (zh) 2015-07-16
IL244454A0 (en) 2016-04-21
US20150232548A1 (en) 2015-08-20
PE20160753A1 (es) 2016-08-01
US20200199215A1 (en) 2020-06-25
BR112016007112A2 (pt) 2017-09-19
JP2017504600A (ja) 2017-02-09
PH12016500482A1 (en) 2016-05-16

Similar Documents

Publication Publication Date Title
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
TWI559931B (en) Combination therapy with an anti-ang2 antibody and a cd40 agonist
BR112015032224A2 (pt) anticorpos anti-fcrh5
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
UY4151Q (es) Vincha con auriculares
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
UY4210Q (es) Silla
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
BR112015023511A2 (pt) tensor
AR097668A1 (es) Colorante-polímero
CL2015002666A1 (es) Formas de dosificación sólidas de antiemético de liberación prolongada
BR112015024771A2 (pt) cateter
UY4314Q (es) Configuracion aplicada en zapato
UY4237Q (es) Taburete
ES1078864Y (es) Carpeta-silla transportable.
MX2015010789A (es) Anticuerpos anti-pcsm.
TWD158466S (zh) 電位治療器
TN2013000364A1 (fr) تصميم جديد لطائرة مدنية ذات مقعد واحد و انظمة سلامة متطورة
TH1501002638A (th) รูปแบบยาที่มีการปลดปล่อยยาแบบออกฤทธิ์เนิ่นของรูโซลิทินิบ
UY4511U (es) Mensula telescopico-rectangular
TN2013000282A1 (fr) الة لخدمة راس النخلة